SCHEMBL6804364

SCHEMBL6804364

CC(=O)c1cc(Cl)sc1N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 3/20 0.48
ALDH1A1 P00352 2/20 0.47
MAPT P10636 5/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.41
PIK3CA P42336 2/20 0.40
PIK3R1 P27986 1/20 0.40
ATM Q13315 1/20 0.39
CHRNA7 P36544 1/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799336 0.84 TSHR (0.41) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL18412843 0.83 ALDH1A1 (0.51) PRKDCALDH1A1MAPTALOX15HSD17B10
SCHEMBL6799329 0.83 HRH4 (0.41) ALDH1A1MAPTALOX15RAB9ANPC1
SCHEMBL18412858 0.82 PRKDC (0.48) PRKDCALDH1A1MAPTALOX15HSD17B10
SCHEMBL18412857 0.79 ALDH1A1 (0.48) PRKDCALDH1A1MAPTALOX15HSD17B10
SCHEMBL18412859 0.79 PRKDC (0.46) PRKDCALDH1A1MAPTALOX15HSD17B10
SCHEMBL18412862 0.77 PRKDC (0.44) PRKDCALDH1A1MAPTALOX15HSD17B10
SCHEMBL6799182 0.74 JUN (0.48) PRKDCALDH1A1MAPTALOX15HSD17B10
SCHEMBL14598726 0.74 POLB (0.44) ALDH1A1MAPTSMN1; SMN2NPSR1LMNA
SCHEMBL18412860 0.72 PRKDC (0.50) PRKDCALDH1A1MAPTALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142976-A1 Pyridylfuran and pyridylthiophene compounds PFIZER INC. 2004-07-22 US disclosed
US-6696470-B2 FOR THERAPY OF ARTHRITIS, ASTHMA, BONE RESORPTION DISEASE, CACHEXIA, CARDIOVASCULAR DISEASE, CEREBRAL MALARIA, CROHN'S DISEASE, DIABETES, FEVER OR MYALGIA DUE TO INFECTION, GOUT, GRAFT VERSUS HOST REACTION, INFLAMMATION OF ORGANS, ETC. PFIZER INC. 2004-02-24 US disclosed
US-20020022729-A1 Pyridylfuran and pyridylthiophene compounds KAWAI AKIYOSHI (JP) 2002-02-21 US disclosed
EP-0853083-B1 Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof PFIZER (US) 2001-09-12 EP disclosed
US-6048880-A THERAPY FOR CYTOKINE SENSITIVE DISEASES PFIZER PHARAMACEUTICALS INC. (JP) 2000-04-11 US disclosed
EP-0853083-A1 Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof PFIZER INC. (US) 1998-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142976-A1 Pyridylfuran and pyridylthiophene compounds MC2R, FCGR2A, OGFR PRKDC 4561/4885ALDH1A1 789/4885MAPT 3265/4885
US-20020022729-A1 Pyridylfuran and pyridylthiophene compounds MC2R, CRHR1, NR3C2 PRKDC 4517/4885ALDH1A1 729/4885MAPT 2662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.